SCHEMBL167057

SCHEMBL167057

CCOC(=O)c1nn(-c2ccc(F)cc2CC=O)cc1OCC

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 9/20 0.48
RAB9A P51151 7/20 0.48
LMNA P02545 1/20 0.48
AURKA O14965 1/20 0.44
ABL1 P00519 1/20 0.44
LCK P06239 1/20 0.44
MET P08581 1/20 0.44
SRC P12931 1/20 0.44
FER P16591 1/20 0.44
AXL P30530 1/20 0.44
CDK8 P49336 1/20 0.44
TYRO3 Q06418 1/20 0.44
MERTK Q12866 1/20 0.44
MAP2K5 Q13163 1/20 0.44
AURKB Q96GD4 1/20 0.44
ALDH1A1 P00352 6/20 0.40
GABRG2 P18507 5/20 0.40
GABRB3 P28472 5/20 0.40
GABRA5 P31644 5/20 0.40
SMN1; SMN2 Q16637 5/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL167525 0.85 AURKA (0.53) NPC1RAB9ALMNAAURKAABL1
SCHEMBL164265 0.85 NPC1 (0.45) NPC1RAB9ALMNAAURKAABL1
SCHEMBL166083 0.83 NPC1 (0.49) NPC1RAB9ALMNAAURKAABL1
SCHEMBL166787 0.81 NPC1 (0.45) NPC1RAB9ALMNAAURKAABL1
SCHEMBL166788 0.81 NPC1 (0.45) NPC1RAB9ALMNAAURKAABL1
SCHEMBL168121 0.78 NPC1 (0.73) NPC1RAB9ALMNAALDH1A1SMN1; SMN2
SCHEMBL18163425 0.76 NPC1 (0.47) NPC1RAB9ALMNAAURKAABL1
SCHEMBL167624 0.75 AURKA (0.52) NPC1RAB9ALMNAAURKAABL1
SCHEMBL168035 0.74 AURKA (0.41) NPC1RAB9ALMNAAURKAABL1
SCHEMBL164749 0.74 AURKA (0.51) NPC1RAB9ALMNAAURKAABL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8999982-B2 Pharmaceutically active compounds as Axl inhibitors LEAD DISCOVERY CENTER GMBH (DE) 2015-04-07 US disclosed
EP-2609091-B1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2014-11-26 EP disclosed
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS MAX-PLANCK-GESELLSCHAFT ZUR FÖRDERUNG DER WISSENSCCHAFTEN E.V. (DE) 2014-01-16 US disclosed
EP-2609091-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS Lead Discovery Center GmbH (DE) 2013-07-03 EP disclosed
WO-2012028332-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS LEAD DISCOVERY CENTER GMBH (DE) 2012-03-08 WO disclosed
EP-2423208-A1 Pharmaceutically active compounds as Axl inhibitors Lead Discovery Center GmbH (DE) 2012-02-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140018365-A1 PHARMACEUTICALLY ACTIVE COMPOUNDS AS AXL INHIBITORS AXL, FLT3, ERBB3 NPC1 3417/4885RAB9A 1235/4885LMNA 4125/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.